Pharmaceutical Manufacturing Market by Formulation, Drug Development Type, Route of Administration, Drugs, Age Group, Distribution Channel, Therapy Area

Description

List of Tables

[181 Pages Report] The Pharmaceutical Manufacturing Market size was estimated at USD 620.68 billion in 2023 and expected to reach USD 672.44 billion in 2024, at a CAGR 8.66% to reach USD 1,110.17 billion by 2030.

Pharmaceutical manufacturing comprises research, development, production, marketing, and distribution of drugs and medicinal products for human use. These products target disease prevention, diagnosis, treatment, and management in various healthcare settings. Key end-users include patients with acute or chronic illnesses, healthcare professionals, clinical trial researchers, insurance companies, and regulatory agencies. Rising aging populations with a higher prevalence of chronic diseases across the globe and increasing need for advanced medicines targeting unmet medical needs influence the growth in the pharmaceutical sector. In addition, rising government funding supports research and development activities in the healthcare sector, allowing new drug development for pharmaceutical companies. However, stringent regulatory requirements imposed by national authorities and the lengthy clinical trial processes create barriers to entry for new pharmaceutical manufacturers.

KEY MARKET STATISTICS
Base Year [2023]	USD 620.68 billion
Estimated Year [2024]	USD 672.44 billion
Forecast Year [2030]	USD 1,110.17 billion
CAGR (%)	8.66%

Moreover, increasing competition from generics and biosimilars and maintaining a robust supply chain pose significant challenges. Furthermore, the technological advancements in drug development processes and a growing focus on personalized medicine create sustainable opportunities for market growth. Also, embracing digital technologies to optimize R&D processes, enhancing the drug development efficiency

Formulation: Surging investment to support robust research and development of injectable formulations

Capsules are preferred for their ease of swallowing and accurate dosing capabilities. They are suitable for both immediate-release and extended-release formulations. Injectable formulations offer rapid onset of action and high bioavailability as they bypass gastrointestinal absorption barriers. These are commonly used for life-saving medications, vaccines, and biopharmaceutical products. Powders are ideal for patients with difficulty swallowing tablets and capsules; they can be reconstituted into convenient oral suspensions and topical applications when needed. Sprays are preferred for localized drug delivery, such as nasal and buccal administration. They offer rapid absorption and high bioavailability, making them ideal for emergency medications. Suspensions provide flexibility in dosing and are suitable for pediatric and senior patients who have difficulty swallowing solid dosage forms. Tablets remain the most popular dosage form due to their portability, ease of manufacturing, and cost-effectiveness. Each formulation type serves specific patient needs based on factors such as administration route, onset of action, bioavailability, dosing accuracy, ease of use, and patient preferences.

Drug Development Type: Increasing use of outsourced pharmaceutical manufacturing due to its cost effectiveness

In-house drug development entails a pharmaceutical company conducting all research and development (R&D), clinical trials, regulatory compliance, production, marketing, and distribution within its organization. Companies that choose this approach often have comprehensive R&D facilities and skilled personnel to manage all aspects of the drug development process in a controlled environment. Outsourcing involves partnering with external organizations, such as contract research and manufacturing organizations, to facilitate various stages of the drug development process. Outsourcing partners may offer services ranging from preclinical studies to post-marketing surveillance. Companies prefer outsourcing if they lack the necessary facilities and expertise for specific drug development phases. Additionally, outsourcing can help control costs and reduce time-to-market by leveraging third-party vendors' specialized knowledge and resources.

Route of Administration: Rising research and development activities parenteral drug delivery with rising prevalence of chronic disease

Inhalation-based drug delivery is primarily preferred for treating respiratory disorders, including asthma, cystic fibrosis, and chronic obstructive pulmonary disease. This route offers a rapid onset of action and improved safety due to targeted lung deposition. Oral administration is the most favored route due to its ease of administration, patient compliance, flexibility in dosage forms, and cost-effectiveness. Parenteral drug delivery includes intravenous (IV), intramuscular (IM), and subcutaneous (SC) injections, offering rapid onset of action with 100% bioavailability, making it ideal for emergency treatments and chronic illnesses requiring long-term care, such as diabetes and cancer. Topical drug administration is particularly suitable for localized treatment of skin disorders such as dermatitis, psoriasis, and acne, and pain relief by applying creams, gels, and patches directly onto the affected area.

Drugs: Inclination toward Over-the-counter (OTC) drugs

Over-the-counter (OTC) drugs are vital in providing consumers with accessible and effective treatments for common ailments. Acetaminophen is a widely used analgesic and effectively relieves mild to moderate pain and alleviates fever in various conditions such as headaches, menstrual cramps, backaches, dental pain, and arthritis. Bismuth subsalicylate is an antacid and anti-diarrheal medication used to treat common gastrointestinal issues such as indigestion, heartburn, nausea, and diarrhea. Dextromethorphan (DXM) is a cough suppressant drug that temporarily relieves the cough reflex in the brain's medulla oblongata region. Hydrocortisone creams are topical corticosteroids designed to treat skin conditions, including eczema, dermatitis, and insect bites, by reducing inflammation and itching. Ibuprofen is commonly used to relieve headaches, dental pain, menstrual cramps, or musculoskeletal injuries. Pseudoephedrine is a nasal decongestant found in many cold medications and relieves congestion by narrowing blood vessels in the nasal passages and reducing swelling and mucus buildup. Prescription medicines require authorization from a healthcare professional before being dispensed by a pharmacist. These medications are often prescribed for more severe or chronic conditions where specialized medical intervention is necessary to ensure safe use and optimal therapeutic outcomes. Acetaminophen Plus Hydrocodone is used to manage moderate to severe pain. Amlodipine works by relaxing blood vessels and improving blood flow and is commonly prescribed for hypertension and angina. Lisinopril expands blood vessels, reduces blood pressure, and is prescribed for hypertension treatment. Metformin is prescribed for type 2 diabetes management alongside dietary changes and exercise programs. Simvastatin lowers cholesterol levels to reduce the risk of heart strokes and other cardiovascular problems.

Age Group: Significant need for drug formulations to treat geriatric medical conditions

Adults require medications for managing chronic conditions such as hypertension, diabetes, cardiovascular diseases, or mental health disorders. Recent trends indicate a growing need for personalized medicine that caters to individual genetic makeup, lifestyle factors, and environmental influences. For children & adolescents, vaccines play a vital role due to school immunization requirements and protection against childhood diseases, including measles or chickenpox. Additionally, there is a need for pediatric formulations that consider dosage accuracy and palatability to ensure medication adherence among children. The geriatric population faces chronic conditions such as dementia, arthritis, or osteoporosis. Medications must be age-appropriate with careful consideration of drug-drug interactions, side effects, and dosing adjustments based on renal and hepatic function. The pharmaceutical manufacturing landscape differs across various age groups regarding medication needs and preferences. While adult medications focus on managing chronic conditions with personalized approaches, pediatric formulations emphasize vaccine development and adherence considerations. Geriatric populations require special attention to drug interactions and dosage adjustments due to age-related physiological changes.

Distribution Channel: Penetration of non-retail distribution channels for pharmaceuticals

Non-retail distribution channels primarily cater to hospitals, clinics, government agencies, long-term care facilities, and other healthcare institutions. This segment involves bulk purchasing of pharmaceutical products by institutional buyers to meet the healthcare needs of patients receiving treatment within these establishments. The preference for non-retail distribution arises from the need for specialized medications that may not be readily available or economically viable through retail channels. Retail distribution caters to individual consumers through pharmacies both online and offline), supermarkets, drugstores, and mail-order services. Customers depend on retail distribution for over-the-counter (OTC) medications, prescription drugs, and other healthcare products that can be quickly and conveniently procured. Retail channels aim to offer consumers a wide range of options, competitive pricing, and personalized services such as medication counseling or health screenings. Non-retail focuses on institutional buyers that require bulk orders of specialized medications, while retail caters to individual consumers seeking convenience, accessibility, and a diverse product range.

Therapy Area: Wave of innovations toward development of new oncology treatment modalities

The increasing prevalence of allergic conditions worldwide drives the need for allergy treatment and drugs. The surge in aging populations and unhealthy lifestyles contributing to heart disease prevalence raises the need for cardiovascular therapies. The rise in a number of dermatology conditions, such as scurvy, dermatitis, and skin infections, necessitates efficient drugs. The rising diabetes epidemic creates a substantial need for effective therapies. Growth in gastrointestinal diseases necessitates advancements in gastroenterology treatments and medicines. Infectious diseases persist globally, requiring continuous vaccine and antiviral development. The rising burden of neurological disorders contributes to a significant need for improved drugs and therapeutics. Cancer remains a leading cause of casualties, driving the need for innovative oncology therapies. Aging populations contribute to increased eye disease prevalence and necessitate ophthalmic treatments. The global burden of chronic pain propels the need for effective analgesics or nonsteroidal anti-inflammatory drugs. Mental health disorders affect millions globally and require therapeutic breakthroughs within psychiatry. Chronic respiratory diseases influence the need for novel pulmonary treatments. The increasing prevalence of kidney disease requires innovative renal therapies. Cases of asthma and COPD necessitate advancements within the respiratory therapy area segment.

Regional Insights

The Americas hold a significant position in the global pharmaceutical market, attributed to its strong research & development (R&D) capabilities, presence of leading pharmaceutical companies, and favorable government policies. The United States has FDA-approved manufacturing facilities focusing on producing biologics and complex generics. European countries, including Germany, France, Switzerland, and the United Kingdom, have advanced pharmaceutical companies with innovative production technologies. These manufacturers have been investing heavily in innovative drug therapies while complying with stringent regulatory standards set by the European Medicines Agency. The Asia Pacific countries initiative aims to boost domestic production and innovation, encouraging investment in R&D and advanced manufacturing technologies. Their policies have led to a surge in new patents filed by pharmaceutical companies. Moreover, the rising investments in healthcare by the private and public sectors in the APAC region fueled the pharmaceutical manufacturing industry.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Pharmaceutical Manufacturing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Pharmaceutical Manufacturing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Pharmaceutical Manufacturing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Actiza Pharmaceutical Pvt. Ltd., Advent Pharma Ltd., Aenova Group GmbH, Amgen Inc., AstraZeneca PLC, Asymchem, Inc., Azurity Pharmaceuticals, Inc., Bayer AG, Biocon Limited, BioNTech SE, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, Emcure Pharmaceuticals Limited, F. Hoffmann-La Roche Ltd., Famar Group, Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Johnson & Johnson Services, Inc., Lonza Group AG, Lupin Limited, McKesson Corporation, Merck KGaA, Moderna, Inc., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Piramal Pharma Limited, Recipharm AB, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., Veranova, L.P., and Zeon Lifesciences Ltd..

Market Segmentation & Coverage

This research report categorizes the Pharmaceutical Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Formulation
- Capsules
- Injectable
- Powders
- Sprays
- Suspensions
- Tablets

Drug Development Type
- In-House
- Outsource

Route of Administration
- Inhalations
- Oral
- Parenteral
- Topical

Drugs
- Over-the-Counter (OTC) Medicines
- Prescription Medicines

Age Group
- Adults
- Children & Adolescents
- Geriatric

Distribution Channel
- Non-Retail
- Retail

Therapy Area
- Allergy
- Cardiovascular Diseases
- Dermatology
- Diabetes
- Gastroenterology
- Infectious Disease
- Neurology
- Oncology
- Ophthalmology
- Pain Management
- Psychiatry
- Pulmonary
- Renal Disease
- Respiratory Diseases

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Pharmaceutical Manufacturing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Pharmaceutical Manufacturing Market?

3. What are the technology trends and regulatory frameworks in the Pharmaceutical Manufacturing Market?

4. What is the market share of the leading vendors in the Pharmaceutical Manufacturing Market?

5. Which modes and strategic moves are suitable for entering the Pharmaceutical Manufacturing Market?

Product Code: MRR-22146147675F

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increase in global demand for vaccines and drugs
  - 5.1.1.2. Growing pharmaceutical R&D spending
  - 5.1.1.3. Growth in geriatric population and incidence rate of chronic disorders
- 5.1.2. Restraints
  - 5.1.2.1. High costs and complexities associated with the pharma production
- 5.1.3. Opportunities
  - 5.1.3.1. Rise in the investment and funding programs in the pharmaceutical manufacturing sector
  - 5.1.3.2. Emergence of novel pharmaceutical manufacturing technologies
- 5.1.4. Challenges
  - 5.1.4.1. Stringent government regulations for pharmaceutical companies
5.2. Market Segmentation Analysis
- 5.2.1. Formulation: Surging investment to support robust research and development of injectable formulations
- 5.2.2. Drug Development Type: Increasing use of outsourced pharmaceutical manufacturing due to its cost effectiveness
- 5.2.3. Route of Administration: Rising research and development activities parenteral drug delivery with rising prevalence of chronic disease
- 5.2.4. Drugs: Inclination toward Over-the-counter (OTC) drugs
- 5.2.5. Age Group: Significant need for drug formulations to treat geriatric medical conditions
- 5.2.6. Distribution Channel: Penetration of non-retail distribution channels for pharmaceuticals
- 5.2.7. Therapy Area: Wave of innovations toward development of new oncology treatment modalities
5.3. Market Trend Analysis
- 5.3.1. Flourishing pharmaceutical industry and burgeoning pharmaceutical investment & exports in the Americas
- 5.3.2. Supportive government initiatives and investments for domestic pharmaceutical manufacturing in the Asia-Pacific
- 5.3.3. Emphasis on R&D of novel drugs and presence of significant pharmaceutical manufacturers in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis
5.8. Client Customization
- 5.8.1. List of Top Selling Prescription and Over-the-Counter Drugs in 2022

6. Pharmaceutical Manufacturing Market, by Formulation

6.1. Introduction
6.2. Capsules
6.3. Injectable
6.4. Powders
6.5. Sprays
6.6. Suspensions
6.7. Tablets

7. Pharmaceutical Manufacturing Market, by Drug Development Type

7.1. Introduction
7.2. In-House
7.3. Outsource

8. Pharmaceutical Manufacturing Market, by Route of Administration

8.1. Introduction
8.2. Inhalations
8.3. Oral
8.4. Parenteral
8.5. Topical

9. Pharmaceutical Manufacturing Market, by Drugs

9.1. Introduction
9.2. Over-the-Counter (OTC) Medicines
9.3. Prescription Medicines

10. Pharmaceutical Manufacturing Market, by Age Group

10.1. Introduction
10.2. Adults
10.3. Children & Adolescents
10.4. Geriatric

11. Pharmaceutical Manufacturing Market, by Distribution Channel

11.1. Introduction
11.2. Non-Retail
11.3. Retail

12. Pharmaceutical Manufacturing Market, by Therapy Area

12.1. Introduction
12.2. Allergy
12.3. Cardiovascular Diseases
12.4. Dermatology
12.5. Diabetes
12.6. Gastroenterology
12.7. Infectious Disease
12.8. Neurology
12.9. Oncology
12.10. Ophthalmology
12.11. Pain Management
12.12. Psychiatry
12.13. Pulmonary
12.14. Renal Disease
12.15. Respiratory Diseases

13. Americas Pharmaceutical Manufacturing Market

13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States

14. Asia-Pacific Pharmaceutical Manufacturing Market

14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam

15. Europe, Middle East & Africa Pharmaceutical Manufacturing Market

15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom

16. Competitive Landscape

16.1. Market Share Analysis, 2023
16.2. FPNV Positioning Matrix, 2023
16.3. Competitive Scenario Analysis
- 16.3.1. INR 15,000 Crore Proposed in Pharma Sector, India
- 16.3.2. Glenmark Pharma Launches Triple-Drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes
- 16.3.3. Novo, Torrent may Widen Tie-Up
- 16.3.4. U.S. FDA Approves Bristol Myers Squibb's Reblozyl (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
- 16.3.5. Finnish Manufacturing Facility to Get EUR 50 Million Expansion
- 16.3.6. Aenova and Galvita Enter Strategic Partnership
- 16.3.7. Novo Nordisk Invests EUR 2.1 Billion in Hillerod Manufacturing Expansion
- 16.3.8. Eli Lilly Adds USD 1.6 Billion to its Manufacturing Spending Plan in Indiana
- 16.3.9. FDA Approves Novartis Millburn Facility for U.S. Commercial Production of Pluvicto
- 16.3.10. Takeda to Invest 100 Billion JPY in a New Manufacturing Facility for Plasma-Derived Therapies in Japan
- 16.3.11. Pfizer Acquires Abzena's Biologic Manufacturing Facility

17. Competitive Portfolio

17.1. Key Company Profiles
17.2. Key Product Portfolio